Barbara Menzaghi

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 371 citations · Full text

Hiv/aids Counselling, Treatment And Prevention, Week 48 +14

Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C

Roberta D’Ambrosio, L. Pasulo, Massimo Puoti et al. · Journal of Hepatology · 2018 · 130 citations

Vaccination, Hepatology, Hepatitis C +10

Weight Gain: A Possible Side Effect of All Antiretrovirals

Lucia Taramasso, Elena Ricci, Barbara Menzaghi et al. · Open Forum Infectious Diseases · 2017 · 88 citations · Full text

Factors Associated With Weight Gain in People Treated With Dolutegravir

Lucia Taramasso, Paolo Bonfanti, Elena Ricci et al. · Open Forum Infectious Diseases · 2020 · 67 citations · Full text

Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients

Daniela Mologni, Paola Citterio, Barbara Menzaghi et al. · AIDS · 2006 · 64 citations